Alkem Laboratories Limited CC-Nov25.pdf · 2025-11-13
Congratulations to the management team for the good set of numbers. A co uple of questions from my side, Gupta, sir. First thing, as you highlighted, the domestic growth trend will continue and FY '27 also, we are confident on the domestic growth part. And in FY '27, '28 also our medical devices business revenue will start to -- the run rate will improve. Enzene will start to clock the INR300 crores annual run rate. Then how should we see the margins from the medium- term perspective from FY '27 onwards?
Okay. So in this year, despite having investments, we are expecting around 50 bps margin expansion and from FY '27 onwards, 1 percentage point margin expansion. Thi s is a fair understanding?